Live Breaking News & Updates on Er2 Negative Advanced Breast Cancer

Stay updated with breaking news from Er2 negative advanced breast cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Breaking Down the Utility of Vepdegestrant in First-Line ER+/HER2– Breast Cancer

Carlos L. Arteaga, MD, discusses the utility of vepdegestrant alone or in combination in patients with ER-positive, HER2-negative advanced breast cancer. ....

United States , Carlosl Arteaga , Lisak Simmons , Haroldc Simmons Comprehensive Cancer Center , Annette Simmons Distinguished University , Ut Southwestern Medical Center , Breast Cancer Research , Annette Simmons Distinguished University Chair , Distinguished Chair , Comprehensive Oncology , Comprehensive Cancer Center , Medical Center , Patients With Er Positive , Er2 Negative Advanced Breast Cancer ,

Dr Sammons on the SONIA Trial of First-Line CDK4/6 Inhibitor Use in HR+/HER2– Breast Cancer

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial. ....

Sarah Sammons , Dana Farber Cancer Institute , Metastatic Breast Cancer Program , Estrogen Receptor Positive , Er2 Negative Advanced Or Metastatic Breast Cancer , Cdk4 6 Inhibitors , Phase 3 Sonia Trial , Hormone Receptor Hr Positive , Er2 Negative Advanced Breast Cancer ,